Explore our
Empowering data-driven decisions in drug discovery
BioLizard’s CTO, Paul Vauterin, shares in European Biopharmaceutical Review how Bio|Verse® empowers researchers to transform complex multi-omics data into actionable insights, enabling faster, safer, and more data-driven drug discovery and biomarker development.
Biomarker discovery 2.0: Using new technologies to access novel insights into human health and disease
Modern biomarker discovery relies on multi-omics and AI/ML to uncover complex disease patterns. BioLizard’s Bio|Mx empowers researchers to integrate diverse datasets, generate actionable insights, and drive biology-focused, data-driven R&D in human health.
Beyond diagnostics: How biomarkers can be used to de-risk drug development
Biomarker discovery enables safer, more efficient drug development. By identifying disease mechanisms and stratifying patient populations, researchers can reduce uncertainty in clinical trials and improve therapeutic outcomes across diverse disease areas.
Microbial network analysis: How to unravel interactions between taxa
Unravel microbial interactions with network analysis. BioLizard shows how similarity, regression, and dynamic networks help detect keystone taxa, predict ecosystem effects, and turn complex microbiome data into actionable biological insights.
Three ways you can extract information from plant microbiomes
Uncover the plant microbiome with BioLizard. From amplicon and shotgun sequencing to meta-omics, these tools provide insights into microbial species, gene expression, and biochemical pathways shaping plant health and resilience.
BioLizard announces the appointment of Caroline Vanovermeire as Chair of the Board
BioLizard appoints Caroline Vanovermeire as Chair of the Board, succeeding André van de Sande. Caroline brings extensive leadership experience to guide BioLizard’s growth and innovation in bioinformatics, data analytics, and life sciences consulting.
Rooted in Science: The importance of plant microbiomes
Plant microbiomes play a vital role in plant health, growth, and resilience. From nutrient uptake to disease suppression, understanding these microbial communities enables sustainable agriculture, improved food quality, and potential benefits for human health. BioLizard provides expert analysis and tools for microbiome research.
Making sense of cells: The role of AI in advancing biomedical and computational biology
At BioLizard’s VAIA Highway Session, experts explored how AI and multi-omics transform biomedical research. From single-cell analysis to precision immunology, the event highlighted cutting-edge tools, explainable AI, and strategies to turn complex data into actionable scientific insights.
BioLizard Appoints Matthew Hall as Director of Business Development
BioLizard welcomes Dr. Matthew Hall as Director of Business Development. With deep experience in Swiss biotech, AI, and strategic partnerships, Matthew will drive BioLizard’s growth across key markets and strengthen our presence at Biopôle and beyond. Meet him at Swiss Biotech Day!
BioLizard and AbnomX announce partnership
BioLizard and AbnomX announce a strategic partnership to accelerate antibody discovery. Combining BioLizard’s advanced analytics with AbnomX’s Antibody-Extractor platform, the collaboration empowers scientists to transform immune repertoire data into actionable insights.